In an attempt to identify subtypes of breast cancer and pinpoint patterns of cell cycle regulatory defects associated with clinical behaviour, proliferation and other transformation associated events, a multitude of cell cycle regulatory proteins were analysed in a material of 113 primary breast cancers. Increased proliferation was observed in two different scenarios; (1) with high cyclin D1 and elevated retinoblastoma protein (pRb) phosphorylation, (cyclin D1 high tumours) or (2) with high cyclin E protein but low cyclin D1 and lack of corresponding pRb phosphorylation (cyclin E high tumours) indicative of an interrupted pRb pathway. Characteristic for cyclin E high tumours were further defects in p53, p27 and bcl-2, while c-erbB2 overexpression and c-myc amplification was found in both cyclin D1
Introduction
The G1/S transition in normal cells is a thoroughly controlled checkpoint where the important decision to initiate DNA-replication or not is taken (Draetta, 1994; Weinberg, 1995) . As has been obvious the last couple of years, aberrations in G1/S regulatory proteins are common in various tumours and aberrant expression of cyclin E and D1, downregulation of p16 and p27 as well as mutation of the retinoblastoma gene (Rb) has frequently been observed in several cancers and it can be hypothesized that G1/S defects might be obligatory in tumour development (Landberg and Roos, 1997; Sandhu and Slingerland, 2000) .
Cyclin D1 links mitogenic signals to cell cycle progression through increased phosphorylation of pRb (Lukas et al., 1996) . Amplification of the encoding cyclin D1 gene, CCND1, resulting in high cyclin D1 protein content, has been observed in a significant numbers of breast cancers and together with impaired cyclin D1 protein degradation potentially cause unbalanced phosphorylation of pRb (Sherr, 1996; Russell et al., 1999) . The relation between cyclin D1 and in vivo pRb phosphorylation in primary breast cancer has nevertheless not been investigated. Overexpression of cyclin D1 has been associated with ERpositivity (Michalides et al., 1996; van Diest et al., 1997) , while the relation to proliferation and survival has been without consensus (Jares et al., 1997; Barnes and Gillett, 1998) . Nevertheless, similar to Gillett et al (1996) , we have observed an association between cyclin D1 overexpression and improved prognosis (Nielsen et al., 1997) . In line with this, Gillett et al (1996) and van Diest et al (1997) also reported an association between cyclin D1 expression and low tumour grade.
Cyclin E is frequently overexpressed in breast cancer even though amplification of the cyclin E gene seems to be rare (Dutta et al., 1995; Nielsen et al., 1996; Porter et al., 1997) . Instead, cyclin E may be deregulated by alteration in the cyclin E degradation pathway (Strohmaier et al., 2001 ) and altered proteolysis, giving rise to low molecular forms of cyclin E with increased activity (Porter et al., 2001) . Cyclin E can also be deregulated secondary to pRb inactivation, causing premature induction of cyclin E transcript and elevation of cyclin E protein (Herrera et al., 1996; Nielsen et al., 1997) .
Both cyclin D1 and E phosphorylate pRb in complex with cdks, but cyclin E is, in contrast to D1, rate limiting for S phase initiation in both pRb wild type and pRb mutated cells (Ohtsubo et al., 1995) . Cyclin D dependent phosphorylation of pRb has been suggested as a prerequisite for activation of cyclin E transcription by E2F (Harbour et al., 1999) , but experimentally induced cyclin E led to S phase initiation in the absence of both cyclin D1 and wild type Rb phosphorylation (Ohtsubo et al., 1995; Alevizopoulos et al., 1997; Lukas et al., 1997; Geng et al., 1999) . These findings strongly argue for a major impact of cyclin E downstream pRb and the normal pRb pathway could thereby in general be assumed to exhibit a linear course in which the cyclin D1 complex phosphorylates pRb, whereby cyclin E activates phosphorylation of downstream targets in the induction of S phase.
As shown by us earlier, the protein content of cyclin D1 and E in breast cancer forms a specific pattern with in general either high cyclin D1 or high cyclin E, a pattern that is strongly linked to the oestrogen receptor status of the tumours. Also, pRb mutated tumours fit into this model and were all included in tumours overexpressing cyclin E with low cyclin D1 protein (Nielsen et al., 1997) . This is in line with other data showing that D cyclins are essential in the progression through the pRb node in normal cells (Draetta, 1994) but cyclin D1 is downregulated as an effect of pRb inactivation by mutation or certain viral proteins, e.g. SV40 (Bartkova et al., 1994; Parry et al., 1995) . Despite the existence of pRb mutated tumours with high cyclin E/low cyclin D1 content there seemed to be several apparently pRb normal tumours within this group and the function of the pRb node in these tumours is not clear.
We have previously reported a discrepancy between in vivo pRb phosphorylation and proliferation proposing that there exist alternatives to the pRb pathway also for tumours with apparent wild type pRb protein (Lode´n et al., 1999) . In this study we have further explored the relation of cyclins D1 and E to the pRb pathway and to proliferation in human breast cancer and analysed the regulation of cyclin E kinase activity in a model system of four breast cancer cell lines transfected with cyclin E. Our results demonstrate that cyclin D1 and E deregulation coincides with different additional alterations and employ contrasting mechanisms to overrule pRb control and suggests that the differential regulation of cyclin E kinase activity plays a central role in functionally separating these two types of unrestrained tumour growth.
Results
Cyclin D1, pRb functionality and proliferation in oestrogen receptor positive and negative tumours
The relation between cyclin D1 protein, Ki-67 LI, and oestrogen receptor, ER, was characterized in 105 primary breast cancers, analysed by Western blotting, immunohistochemistry and Elisa, respectively, as illustrated in Figure 1 . Tumours with increasing cyclin D1 protein content showed proportional proliferation increase and these tumours were predominately ER positive. In contrast, tumours with low cyclin D1 were ER negative but showed even higher and more dispersed proliferative capacity. As shown earlier, all pRb inactivated tumours in this tumour material were ER negative with low cyclin D1 (Nielsen et al., 1997) . It thus seems to exist two alternative proliferative routes for breast cancer, either through (1) increased cyclin D1 protein associated with oestrogen receptor positivity or (2) without cyclin D1 and oestrogen receptor.
As cyclin D1 and E exhibit different roles at the pRb node with cyclin D1 upstream and cyclin E rather downstream pRb, we sought to explore the linearity of the pRb pathway and identify possible sites of interruption. We therefore characterized in vivo pRb phosphorylation in comparison to cyclin D1 and E contents, cyclin E kinase activity and Ki-67 in ER positive and negative tumours. pRb phosphorylation was defined as the percentage of the upper phosphorylated band relative to total pRb ( Figure 2 ). Tumours with inactivated pRb (determined by immunohistochemistry, Nielsen et al., 1997) were excluded in the analyses involving pRb phosphorylation.
In ER positive tumours, pRb phosphorylation was associated with cyclin D1 and E protein levels, cyclin E kinase activity and Ki-67 (Table 1 ), suggesting that the signal cascade from cyclin D1 through phosphorylation of pRb and activation of cyclin E kinase to a proliferative response was preserved and involved as an intact pRb protein. As shown by as earlier cyclin D1 and E were overexpressed in partly different (Nielsen et al., 1997) , strongly coinciding with ER positive and negative breast cancer, respectively (Figure 3 ). The data presented above therefore suggest that, as a main mechanism in ER positive breast cancer, the pRb pathway is deregulated by cyclin D1 mediated hyperphosphorylation of pRb.
In ER negative tumours, data were indicative of cyclin D1 and cyclin E dependent phosphorylations of pRb. However, a negative correlation between cyclin D1 and Ki-67 in addition to a lack of association between pRb phosphorylation and Ki-67 suggested that pRb did not regulate proliferation in this group of tumours. Instead, correlations between cyclin E, cyclin E kinase and Ki-67 suggest that proliferation was controlled downstream pRb, despite the obvious existence of tumours with wild type pRb (Nielsen et al., 1997) .
High cyclin E has been strongly correlated with increased proliferation , and as stated above, cyclin E was predominately overexpressed in the ER negative cancer (Nielsen et al., 1997) . Cyclin E overexpresing tumours thereby fall into the category of ER negative tumour with high proliferation, but low cyclin D1 (Figures 1 and 2) . Thus, these data suggest a second pRb deregulative mechanism; overexpression of cyclin E, or associated events, may interrupt the pRb pathway, resulting in high proliferation in the absence of pRb control.
Deregulation of the pRb pathway by cyclin D1 and E and association with other genetic defects Deregulation of cyclin D1 or E consequently may represent two alternative strategies for breast cancer to overcome growth control and potentially also represent different pathways in the transformation process. To test these hypothesis tumours were divided into cyclin D1 high , cyclin E high or cyclin low ( Figure 3 ). Clinicopathological factors and the presence of aberrations in a set of transforming associated proteins (p53, p21, p27, p16, bcl-2, c-myc and c-erb-B-2) were then analysed in the three groups, as detailed below.
As displayed in Figure 3 , a small fraction of the tumours (9%) had high protein content of both cyclin D1 and cyclin E as presented earlier, and were not simply classified in the cyclin D1 high or cyclin E high The number of tumours in each test differed as five tumours lacked Ki-67 characteristics (Nielsen et al., 1997) , and the cyclin E kinase activity was characterized in a limited number of tumours (Lode´n et al., 1999) . Besides these limitations, and the exclusion of pRb mutated tumours in the tests involving pRb phosphorylation, the maximal number of data available in each individual test was used for statistical evaluation Figure 3 Cyclin D1 versus cyclin E protein expression with oestrogen receptor status indicated. Lines indicate cut-offs for high cyclin D1 and cyclin E expression (0.75 and 0.5, respectively). Tumours classified as cyclin low , cyclin D1 high or cyclin E high are shown in the insert subgroups. However, there were several indications that these tumours indeed were functionally related to tumours with high cyclin D1. Tumours with high levels of both cyclin D1 and E were predominately ER positive and the rise in cyclin E therefore in part represented an expected increase due to high proliferation in this subgroup. Gene amplification of the gene encoding cyclin D1, CCND1 (data presented below) was, in contrast to the gene encoding cyclin E, CCNE, frequent among tumours with combined high cyclin D1 and E, underlining that cyclin D1, rather than cyclin E, was deregulated. CCNE amplification was detected in two tumours but only one of these overexpressed the protein. pRb phosphorylation was significantly associated with Ki-67 as well as to both cyclin D1 and E levels within the combined group of high cyclin D1 and high cyclin D1/E tumours, emphasising that pRb phosphorylation was essential for proliferation in these tumours (data not shown).
Cyclin E high tumours were associated with increased tumour size, nuclear pleomorphism and higher proliferation whereas cyclin D1 high tumours affected older women (Table 2a ). The three tumour groups also differed in survival (P=0.0112) with a median follow up of 79 months. As illustrated in Figure 4 , there was a striking difference over time in survival for patients with cyclin D1
high and E high tumours (median survival times of 85.2 and 41.7 months, respectively), but the three survival curves also seemed to converge with times. ER status was the only independent prognostic factor in a multivariate analysis including ER status, cyclin status and proliferation (data not shown).
Aberrations in p53, p21, p27 and p16 have been detailed previously (Nielsen et al., 1997; Roos et al., 1998; Lode´n et al., 1999) . Due to the high p16 protein is associating with pRb inactivation, these tumours were excluded in the analyses of p16 (Parry et al., 1995; Nielsen et al., 1997) . Criteria for immunohistochemical evaluation of bcl-2 and c-erb-B-2, as well as analyses of c-myc amplification, are specified in Material and methods. There were significant differences in p53, p27 and bcl-2 aberrations between the three groups, and these alterations were primarily associated with upregulation of cyclin E, rather than cyclin D1 (Table  2b) . p21 was more frequently expressed in p53 wild type tumours rather than following the pattern of cyclin D1 and E (data not shown), while c-erb-B-2 overexpression was not restricted to any group. Considering all tumours, c-myc amplification was strongly associated with increased Ki-67 (P=0.003), and increased copy number of c-myc was represented in both cyclin D1 high and cyclin E high tumours ( Figure  5 ).
Impact of accumulation of defects on deregulation of cyclin E kinase activity
Our results suggest that the signal cascade inducing S phase pass the level of cyclin E kinase activity, irrespective of pRb control, thereby making the cyclin E kinase activity a key regulatory event in the G1/S transition. To further investigate the possible impact of differential accumulation of defects on the deregulation of the cyclin E kinase activity, we upregulated cyclin E in a model system of four breast cancer cell lines and characterized the activity and composition of the cyclin E complex.
Cyclin E cDNA was transfected into two ER positive cell lines, MCF-7 and T-47D, and two ER negative cell lines, MDA-MD-468 and BT-549. MCF-7 overexpressed cyclin D1 (Russell et al., 1999) , whereas BT-549 and MDA-MD-468 had deficient pRb (T'ang et al., 1988) and p53 (Bartek et al., 1992) . These cell lines will therefore be representative for the genetic background in the cyclin D1
high and E high pathways, while the normal pRb (T'ang et al., 1988) , and moderate cyclin D1 levels in T-47D suggest a cyclin low background, Figure 6a -c) .
Cyclin E overexpression resulted in two main bands of approximately 48 and 42 kDa (Figure 6a ). Levels of overexpressed cyclin E was approximately 3 -4 times higher compared with the endogenous 51 kDa cyclin E and within the range of total cyclin E protein observed in primary breast cancers (Figure 6d) . Cyclin E immunoprecipitates were analysed for coprecipitation of cdk2, p21 and p27 and cyclin E kinase activity (Figure 6a,b) . To present the change in the cyclin E complex following transfection with cyclin E, first, cyclin E levels, contents of CKI in the complexes as well as cyclin E kinase activity in each transfected cell line were determined. The quotient between the levels and kinase activities in cyclin E transfectants, compared with corresponding cell line transfected with empty vector, were then calculated and presented in Figure 6e .
In general, there was a greater increase in cyclin E kinase activity in the two cyclin E high cell lines and for MDA-MD-468 the rise in kinase activity was comparable to the corresponding increase in total cyclin E. In spite of a nearly fourfold upregulation of cyclin E in the cyclin D1
high MCF-7, the kinase activity was unaffected. In both T-47D and MCF-7, there was no change in total levels of p27 but a redirection of p27 to the cyclin E complex. In MCF-7, p53, as well as p21, was modestly induced but there was a marked Cyclins and inactivation of the pRb pathway M Lodén et al redirection of p21 to cyclin E. Thus, the genetic background of the cyclin D1 high cell line suppressed the potential response in cyclin E kinase activity following transfection of cyclin E. In contrast, the cyclin E high cell line MDA-MD-468 lacked compensatory mechanism resulting in a cyclin E complex mainly regulated by cyclin E.
Progression from cyclin D1
high to cyclin E high tumours
We further wanted to ascertain whether cyclin D1 high tumours could switch pathway to a pRb independent, cyclin E high phenotype. The rationale was that inactivation of both pRb and p53, overrepresented in cyclin E high tumours, as well as c-myc, has been implicated in downregulation of cyclin D1 in experimental systems, suggesting that these alterations besides other mechanisms, might have caused the downregulation of cyclin D1 also in primary breast tumours (Jansen-Du¨rr et al., 1993; Mu¨ller et al., 1994; Parry et al., 1995; Spitkovsky et al., 1995) . A cyclin D1 amplified tumour or precancerous stage that experienced a secondary downregulation of cyclin D1 would therefore display cyclin D1 amplification but lack cyclin D1 protein. As low cyclin D1 protein expression in this context could also be the result of diminished proliferation, we considered that a parallel increase in cyclin E, as well as in Ki-67, was necessary to support a conversion into pRb independent growth.
For this purpose, we characterized the presence of amplification of CCND1, in the breast cancer material by Southern blotting hybridization. Amplification was detected in 14 out of 100 tumours and was significantly associated to cyclin D1 protein levels (P50.0001). We next performed FISH, probed against CCND1, and evaluated the protein content of cyclin D1 and E in sequential paraffin slices. FISH was also performed on imprint touch preparations from semi-thorn tumours that were subsequently homogenized and analysed for cyclin D1 and E protein by Western blotting, as presented in Table 3 . Despite some inconsistency between the different parts of the tumours investigated, a total of three out of 21 tumours fulfilled our criteria thus suggesting an abandoned cyclin D1 high pathway (Table 3 and Figure 7a,b) . Interestingly, all three tumours with this pattern also displayed low p16 protein, in U165 explained by hypermethylation of the p16INK4A promoter (Nielsen et al., 2001) , possibly indicating that the cdk4 complex had been targeted by a combined cyclin D1 upregulation/p16 downregulation before processing to a cyclin E high phenotype.
Discussion
In this study we have tried to delineate the function of the pRb node in human breast cancer using both primary tumours and breast cancer cell lines. Key regulatory events such as cyclin E associated kinase activity and proliferative pathways were pinpointed in the tumour material whereas cell lines and transfection experiments were used as model systems representing different pathways observed in the tumours. The advantage with this approach is that complex associations between aberrations in the G1/S transition control in breast cancer are preferably studied in primary tumours and not in cell lines that are selected for certain growth properties, while cell lines on the other hand can be easily manipulated to overexpress certain genetic key targets, making it possible to study secondary alterations and compensatory mechanisms. By examining the pattern of cell cycle deregulation in relation to in vivo pRb phosphorylation and proliferation, we distinguished here two main groups of tumours which seem to have adopted different strategies to inactive pRb control, either by pRb hyperphosphorylation, as in the cyclin D1 high subgroup, or by interfering with pRb control by alterations downstream pRb, as in the cylin E high tumours. The cyclin E high group consisted of not only pRb inactivated, but also pRb wild type tumours, in general with very low cyclin D1 levels. Cyclin D1 has no cdk4 dependent role in pRb mutated cells (Bartkova et al., 1994) , but lack of correlation between pRb phosphorylation and proliferation in the remaining pRb wild type, cyclin E high tumours, suggest that pRb phosphorylation was not in control of proliferation in this group. A number of experimental approaches by others have suggested a role of cyclin E kinase downstream the pRb pathway in the G1/S transition: Lukas et al (1996) and Santoni-Rugiu et al. (2000) , demonstrated that ectopic expression of cyclin E or c-myc could overcome a G1 block imposed by p16 or a phosphorylation deficient pRb, pRbdeltacdk2. Induction of S phase by cyclin E in these experiments occurred in the absence of E2F-transactivation, demonstrating the presence of cyclin E dependent targets other than the pRb/p107/p130 family. Such substrates have been identified, e.g. NPAT (Zhao et al., 1998) . As reported by Alevizopoulos et al (1997) and Santoni-Rugiu et al. (2000) , c-myc induced S phase through its action upstream cyclin E kinase, via transcriptional activation of cdc25A, and possibly also sequestering of p27. These results provided evidence for a role of cyclin E kinase in promoting S phase downstream pRb and independently of E2F. Alterations that deregulate the cyclin E kinase, as the frequent downregulation of p27 in cyclin E high tumours (this study), may therefore hypothetically be candidates that uncouple pRb control in breast cancer.
Our transfection experiments demonstrated that cyclin E to a higher degree controlled the cyclin E kinase activity in the cyclin E high cell lines compare to the others. This was expected, as the cyclin E high cells were associated with a lack of p27 and p53, as in cyclin E high tumours, and thereby unable to induce and redirect CKIs to the cyclin E complex. However, the cyclin E kinase in MDA-MD-468 was largely controlled by cyclin E, suggesting that in addition to lack of CKIs, this cell line is also deficient in other mechanisms to compensate for the increased cyclin E. Possible, such a genetic background of accumulated alterations that give rise to an uncontrolled cyclin E kinase may contribute to the uncoupling of pRb control, as suggested in the cyclin E high tumours. In contrast to tumours with high cyclin E, our results suggest that the main mechanism whereby cyclin D1 induce proliferation is through hyperphosphorylation of pRb. However, by direct comparison with the cyclin E high tumours, the cyclin D1 high type of growth, seem to be associated with less proliferative capacity, higher differentiation characteristics, and a more favourable outcome. The adoption of tumours into pRb dependent and pRb independent mechanisms may therefore be one explanation for the lack of relationship between cyclin D1 and proliferation previously reported (Gillett et al., 1996; Jares et al., 1997) . However, even though cyclin D1 increased proliferation, this increase was not coupled to a corresponding worse patient survival.
Besides the differences in frequency of p27 alterations, proliferation and survival, as discussed above, Comparison of cyclin E expression in MCF-7, transfected with cyclin E, and primary breast tumours. (e) Contents of cyclin E, cyclin E kinase activity and cyclin E complexed p27 and p21, presented as the quote between cyclin E and control vector transfectants and ER status (Nielsen et al., 1997) , the tumour groups also differed in age and frequency of alterations in p53 and bc2-l. Even though p16, c-erbB2 and c-myc were not restricted to any of the two groups, these findings underline that the type of pRb deregulative mechanism also may influence the diversity of tumours into different tumour-evolutionary pathways. At least for p27, the role in promoting nuclear import and stabilizing the cdk/cyclin D1 complex (LaBaer et al., 1997; Cheng et al., 1999) may account for the functional separation into cyclin D1
high and E high tumours. Transfection of the cyclin D1 high cell line with cyclin E, resulted in induction and redirection of CKIs to the cyclin E complex, inhibiting any rise in cyclin E kinase. The genetic background associated with cyclin D1 thereby seem to exert a strong control of the cyclin E kinase. This suggests that deregulation of cyclin E has a minor role in cyclin D1 high cells, markedly contrasting to the role in cyclin E high cell lines. Interestingly, c-myc amplification was similarly detected in both cyclin D1
high and E high tumours and thus seemed to promote proliferation independently of the general pRb deregulative mechanism in play. Indeed, c-myc affects multiple targets in the G/S transition (Nasi et al., 2001 ). C-myc may play a role in cyclin E high tumours by targeting cyclin E kinase, as discussed above, but c-myc also upregulates D cyclins and cdk4, which push pRb phosphorylation in addition to increase sequestering of p27 (Mateyak et al., 1999; Copy number CCND1, and the centromere of chromsome 11, was determined by FISH on both tumour imprints and paraffin sections. Centromere copy numbers were in general 2 -4, with exceptions detailed as follows. Tumours were classified as cyclin D1 high , cyclin E high or cyclin low , based on protein contents of cyclin D1 and cyclin E in two protein extracts (SDS-, Figure 2 and RIPA-extracts, Figure 7c ) and cyclin D1, cyclin E and Ki-67 LI in paraffin sections, Figure 7a . The results were similar in the three analyses, with exceptions detailed as follows. f U156 was classified as cyclin E high by analyses in SDS-extracts and paraffin sections, while as cyclin low in RIPA extracts. g U266 was classified as cyclin D1 high in SDS-extracts, while cyclin E high in the paraffin section. Pe´rez-Roger et al., 1999) . Thus, both cyclin D1 and E dependent mechanisms may benefit from c-myc activation.
As cyclin D1 high tumours had better prognosis compared to cyclin E high tumours, the issue whether or not these tumours can progress to clinically more aggressive and proliferative cyclin E high tumours is important. We observed a relative low frequency of tumours with the pattern of CCND1 amplification but with low cyclin D1/high cyclin E protein/high proliferation, indicating an abandoned cyclin D1 high path. Bartkova et al., 1994 reported a similarly low frequency of loss of cyclin D1 positivity in recurrent tumours compared to the primary tumour. One of the main findings in this report is that cyclin D1 high and cyclin E high tumours accumulate different additional alterations. Possibly, the genetic background in cyclin D1 high cells may simply reject alterations that mediate a bypass of the pRb pathway, similar to the suppression of cyclin E kinase activity in the cyclin D1 high cell line when exposed to high cyclin E.
In summary, our results support a model in which tumours in general use alternative strategies to inactivate pRb which may further influence division into distinct tumour-evolutionary pathways, Figure 8 . In spite of some inconsistency, aberrant pRb, p53 and p27 (this study (data not shown); Bosari and Viale, 1995; Slingerland and Pagano, 2000) have been shown to be associated with poor patient outcome and alterations in these molecules was limited in cyclin D1 high but pronounced in the cyclin E high pathway. In comparison with cyclin D1 high tumours, the potential independence from pRb control in the cyclin E high tumours seemed to be associated with a more substantial lack of G1/S control with a more aggressive disease and increased mortality. Therefore, the complex interplay between the factors generating the separate pRb inactivating mechanisms probably all contribute to the specific behaviour and outcome associated with the two proposed tumorogenic pathways represented by cyclin D1
high and E high breast cancer. The patients in this study have obtained alternative treatments but the number of patients is too low for any conclusions concerning effects of treatments to be made. Future studies have to reveal possible predictive information regarding cyclin subgroups and different treatment strategies.
Materials and methods

Tumour samples
Diagnostic tumour samples were collected from 113 patients with breast carcinoma. According to the classification from The International Union Against Cancer, 30 patients had stage I, 63 patients stage II, two patients stage III and 8 patients stage IV. Ten patients had unknown disease stage owing to unknown tumour size or axillary node status. No patient had been treated with radiation or chemotherapy before sampling. All tumours were snap frozen in liquid nitrogen and stored in 7808C until extracts for DNA and protein analyses were prepared.
Breast cancer cell lines and stable transfectants
All cell lines obtained from American Type Culture Collection (ATCC Int, UK) were grown in RPMI 1640, supplemented with 10% foetal calf-serum and antibiotics. CCNE cDNA (kind gift from Steven Reed, Scripps Research Institute, La Jolla, CA, USA) was placed in front of a CMV promotor in pcDNA-3 and the construct was stably transfected into cells using either DOPAT or Lipofectamin plus (Life Technologies, CA, USA). Single colonies of cyclin E transfectants were screened for high expression of cyclin E using flow cytometry and Western blotting (data not shown).
Immunohistochemistry and p53 mutation analyses
Breast cancer specimens were fixed in formalin and embedded in paraffin according to the clinical routine. Fixation time in formalin varied slightly between different samples but were in general between 15 -24 h. Paraffin embedded sections were dried, deparaffinized, rehydrated and microwave treated according to standard procedures before being processed in an automatic immunohistochemistry staining machine (Ventana 320-202, Ventana Inc. AZ, USA) using monoclonal antibodies against Bcl-2 or erb-B-2 (Daco, Copenhagen, Denmark). Bcl-2 expression was classified into four groups based on absent, weak, moderate or strong cytoplasmic staining of invasive tumour cells. Tumours with staining comparable with lymphocytes were considered normal/high (48%) while less intense staining in 52% of tumours were considered low (Gee et al., 1994; Zhang et al., 1997) . C-erb-B-2 was similarly classified in four group and strong membrane staining of c-erb-B-2 protein was detected in 18% of tumours (Re´villion et al., 1997) . Staining of p27, p53, pRb and Ki-67 have been described elsewhere (Nielsen et al., 1997; Roos et al., 1998; Lode´n et al., 1999) . PCR amplification of exons 5 -8 of the p53 gene and single strand polymorphism (SSCP) were performed as detailed previously (Roos et al., 1998) .
Western blotting, immunoprecipitation and cyclin E kinase activity
Western blotting has been described elsewhere (Nielsen et al., 1996) . Nitro-cellulose membranes were incubated with antibodies against cyclin E (HE-12), cdk2 (M2), p27 (C-19), pRb (IF8, all from Santa Cruz, CA, USA), p21 (Ab-1), p53 (Ab-6), cyclin D1 (Ab-3, all three from Calbiochem, UK), or actin (Boeringer-Mannheim GmbH, Germany). Immunoprecipitation and measurement of cyclin E kinase activity has been described elsewhere (Lode´n et al., 1999) . Briefly, 80 g of total proteins were immunoprecipitated for 1 h using agarose-conjugated antibodies against cyclin E (HE-111, Santa Cruz, USA). The agarose pellets were either separated on SDS -PAGE for Western analysis or subjected to cyclin E-kinase measurement. The experiments concerning MCF-7 transfectants were repeated three times with the same results, while the results from transfectants of the other three cell lines were based on one experiment. Kinase activity measurement of all transfectants was performed in triplets.
Southern blotting
Tumours were digested in SDS (sodium dodecyl sulphate)-containing buffer by proteinase-K, DNA extracted by phenol/ chloroform, ethanol precipitated and then resuspended in 10 mM Tris buffer (pH 8.0). Five mg DNA was digested overnight with 50 units of EcoRI (New England Biolabs Inc., USA) according to the manufacturer's instructions. DNA fragments were separated on 1% agarose gels, blotted onto nylon membranes (Hybond-N, Amersham Ltd., UK) by capillary transfer in 206SSC solution and immobilized by UV-cross linking. Cyclin E and D1 cDNAs (gift of Dr SI Reed) were labelled by random priming (Megaprime System, Amersham) and hybridization performed in QuickHyb solution (Stratagene Inc., USA) as recommended by the manufacturer with a final high stringency wash in 0.16SSC and 0.1% SDS buffer at 638C for 30 min. To calculate gene copy number the hybridization signal as compared to that from normal breast gland DNA included on every gel and thus represents amplification relatively to diploid gene copy number. To compensate for loading differences and possible tumour aneuploidy membranes were in addition hybridized with a probe for a gene located in the same chromosome regions as the two cyclins. For cyclin E, the insulin receptor gene located on chromosome 19p was used and for cyclin D1 the Ets1 gene was used. Gene copy numbers equal to or higher than two were considered as evidence of gene amplification. Films were exposed between 3 days and 1 week.
Fluorescence In Situ Hybridization (FISH)
Fluorescence In Situ Hybridization (FISH) were performed using a mixture of two direct-labelled probes, directed against CCND1 and the centromere of chromosome 11, respectively (LSI cyclin D1 (11q13) SpectrumOrange/CEP 11 SpectrumGreen, Vysis, Inc., IL, USA). FISH on tumour imprints and paraffin-embedded sections were performed according to the standard protocol recommended by the manufacturer and according to 'FISH on paraffin-embedded tissue sections', Protocol collection for Fluorescence In Situ Hybridization (FISH) on Tissue Sections using direct-labelled DNA Probes, Vysis Inc., respectively. One-colour c-myc FISH on paraffin embedded tumour array sections was performed according to LSI 1 Locus Specific Identifier DNA Probes (Vysis, Inc., IL, USA). Briefly, sections were de-paraffinized 3610 min, treated with 99.9% ethanol 265 min and air-dried at 45 -508C. Sections were incubated with Dako's (Denmark) TRS pH 7.5 for 265 min. After microwave treatment, sections were allowed to cool and washed in purified water for three min. Sections were incubated with 100 ml pepsin solution (Digest-All 3; Zymed, South San Francisco, CA, USA) at 378C for 15 min. After one wash with purified water for three min, sections were air-dried at 45 -508C. Sections were incubated in buffer containing 10% PFA at RT for 10 min followed by one wash with purified water for 3 min and airdried at 45 -508C. Denaturing solution was added and sections were incubated at 758C for 5 min followed by dehydration using graded ethanol. Sections were air-dried at 45 -508C and thereafter the probe (LSI c-myc; Vysis, Downers Grove, Illinois, USA) was added and hybridized at 378C overnight. After-treatment of the sections was done according to manufacturer's protocol. Hybridizations were evaluated using a fluorescence microscope. C-myc was analysed by FISH into two groups characterized by; no amplification ; or low grade amplification, 2 -5 copies; and high grade amplification, 46 copies.
Statistical methods
Associations between linear parameters were calculated using Spearman's two-tail significance test while the Kruskal-Wallis non-parametric significance test was applied when comparing a linear and a grouped parameter. Differences between groups were tested using the log-rank test. The KaplanMeier method was used in calculating survival curves and all calculations were performed in SPSS version 10.0 (SPSS inc., IL, USA).
